George A. Scangos Sells 4,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Share on StockTwits

Exelixis, Inc. (NASDAQ:EXEL) Director George A. Scangos sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $20.14, for a total transaction of $80,560.00. Following the transaction, the director now directly owns 1,034,031 shares in the company, valued at $20,825,384.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ EXEL opened at $20.77 on Friday. The company has a quick ratio of 6.80, a current ratio of 6.89 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $6.15 billion, a PE ratio of 17.31, a price-to-earnings-growth ratio of 2.93 and a beta of 1.93. The company has a 50 day moving average price of $18.54 and a two-hundred day moving average price of $18.28. Exelixis, Inc. has a 12-month low of $15.02 and a 12-month high of $25.31.

A number of hedge funds and other institutional investors have recently bought and sold shares of EXEL. Voya Investment Management LLC lifted its stake in shares of Exelixis by 3.1% in the third quarter. Voya Investment Management LLC now owns 283,322 shares of the biotechnology company’s stock worth $5,010,000 after buying an additional 8,551 shares during the last quarter. Virtu Financial LLC lifted its stake in shares of Exelixis by 107.5% in the third quarter. Virtu Financial LLC now owns 55,353 shares of the biotechnology company’s stock worth $979,000 after buying an additional 28,681 shares during the last quarter. Nomura Holdings Inc. lifted its stake in shares of Exelixis by 52.3% in the third quarter. Nomura Holdings Inc. now owns 49,500 shares of the biotechnology company’s stock worth $880,000 after buying an additional 17,000 shares during the last quarter. Symmetry Partners LLC acquired a new stake in shares of Exelixis in the third quarter worth $185,000. Finally, Squarepoint Ops LLC lifted its stake in shares of Exelixis by 174.7% in the third quarter. Squarepoint Ops LLC now owns 305,778 shares of the biotechnology company’s stock worth $5,408,000 after buying an additional 194,446 shares during the last quarter. Hedge funds and other institutional investors own 77.01% of the company’s stock.

A number of research analysts recently commented on the stock. William Blair reaffirmed a “buy” rating on shares of Exelixis in a research report on Friday. Bank of America reaffirmed a “buy” rating and set a $21.00 price objective (down from $22.00) on shares of Exelixis in a research report on Monday, January 13th. TheStreet downgraded shares of Exelixis from a “b-” rating to a “c” rating in a research report on Friday, November 22nd. Piper Sandler reaffirmed a “buy” rating and set a $35.00 price objective on shares of Exelixis in a research report on Tuesday. Finally, ValuEngine raised shares of Exelixis from a “sell” rating to a “hold” rating in a research report on Tuesday, December 3rd. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $26.09.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: What is the Nikkei 225 index?    

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jefferies Financial Group Boosts Mimecast  Price Target to $60.00
Jefferies Financial Group Boosts Mimecast Price Target to $60.00
Goldman Sachs Group Raises RingCentral  Price Target to $255.00
Goldman Sachs Group Raises RingCentral Price Target to $255.00
Insider Selling: Peoples Utah Bancorp  Director Sells $103,237.50 in Stock
Insider Selling: Peoples Utah Bancorp Director Sells $103,237.50 in Stock
Wells Fargo & Co Increases NVIDIA  Price Target to $290.00
Wells Fargo & Co Increases NVIDIA Price Target to $290.00
Viad Corp  Insider David W. Barry Purchases 1,580 Shares
Viad Corp Insider David W. Barry Purchases 1,580 Shares
Insider Selling: Norwood Financial Co.  SVP Sells 2,005 Shares of Stock
Insider Selling: Norwood Financial Co. SVP Sells 2,005 Shares of Stock


 
© 2006-2020 Zolmax.